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Abstract
Background: The aim of this prospective study is to identify the biomarkers associated with the effects of induction
chemotherapy (iCHT) in terms of the favorable/weaker response to the treatment in locally advanced head and neck
squamous cells carcinomas (LA-HNSCC).
Methods: The studied group consisted of 53 LA-HNSCC patients treated with iCHT. The treatment tolerance was
measured by the Common Terminology Criteria for Adverse Events (CTCAE). The response to the treatment was
evaluated by the clinical, fiberoptic and radiological examinations made before and after iCHT (the TNM Classification
of Malignant Tumors was used for classifying the extent of cancer spread). Proton nuclear magnetic resonance (1H
NMR) serum spectra of the samples collected before and after iCHT were acquired with a 400 MHz spectrometer and
analyzed using the multivariate and univariate statistical methods.
Results: The molecular response to iCHT involves an increase of the serum lipids which is accompanied by the
simultaneous decrease of alanine, glucose and N-acetyl-glycoprotein (NAG). Furthermore, in males, the iCHT induced
changes in the lipid signals and NAG significantly correlate with the regression of the primary tumor. The OPLS-DA
multivariate model identified two subgroups of the patients with a weaker metabolic and clinical response. The first
one consisted of the patients with a significantly lower initial nodal stage, the second one showed no differences in
the initial clinical and metabolic statuses.
Conclusions: The NMR-based metabolomic study of the serum spectra revealed that iCHT induces the marked changes in
the LA-HNSCC patients’metabolic profiles and makes it possible to stratify the patients according to their response to iCHT.
These effects are sex dependent. Further studies on a larger scale accounting for sex and the clinical and metabolic factors
are warranted.
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Background
iCHT in the treatment of LA-HNSCC [1–3] is based on
two standard regimens, which are the TPF schedule (do-
cetaxel, cisplatin and 5-fluorouracil) and the PF schedule
(cisplatin and 5-fluorouracil). TPF demonstrates a less
favorable toxicity profile and a better response rate [4,
5]. Severe hematological adverse events (e.g. leukopenia,
neutropenia, anemia) are more often reported in TPF
[6–8], while non-hematological adverse events (e.g. mu-
cositis, nausea, vomiting) seem to be higher in PF [6–9].
It is suggested that sex is among other factors, like age,
performance status, disease status, lesion size, medica-
tion exposure and comorbidities, that may contribute,
via the genetic, hormonal and molecular pathways, to
the chemotherapy efficacy and its toxicity [10, 11].
Despite the improvements in treatment and new ther-
apies, the survival rates in LA-HNSCC remain stagnant
[12–14]. Thus, there is the urgent need for novel ap-
proaches that can be used to monitor both the toler-
ability and the treatment efficacy. Especially body fluid
and liquid biopsy biomarkers appear to hold a strong
potential for development the tools for such applica-
tions that could direct anticancer therapies in HNSCC
[15]. In recent years, there is an increasing number of
the reports based on the metabolomic approaches
attempting to monitor chemotherapy side effects and
its efficacy in various cancer types [16–21]. In head and
neck cancers Ye at al. revealed the important metabolic
differences in the iCHT efficacy between the responsive
and unresponsive patients using the chromatographic
methods [21]. They compared the pre- and post-
chemotherapy serum samples and found that induction
chemotherapy induces various metabolic changes, e.g.
in carbohydrate metabolism, amino acid metabolism,
fatty acid metabolism and steroid metabolism. Lactic
acid, glutamic acid, and aspartic acid were even defined
as the potential biomarkers of the iCHT efficacy [21].
On the other hand, Jelonek et al. [22] analyzed the
chromatographic profiles of the sera of the HNSCC pa-
tients treated with concurrent chemo-radiotherapy or
radiotherapy alone with or without prior induction
chemotherapy. They detected the differences in the
molecular responses to the various treatment modal-
ities, hypothetically associated with a different risk of
toxicity, however no metabolic abundance changes be-
tween the pre- and post-treatment samples in case of
iCHT were observed, presumably due to restricting
their study only to the first iCHT cycle.
In the current work we decided to perform the NMR-
based study of the influence of iCHT on the serum
metabolome of the LA-HNSCC patients to identify the
NMR biomarkers of the iCHT-induced metabolic
changes and to assess their relationships with the re-
sponse to treatment.
It may be hypothesized that such NMR approach may
help to differentiate the well responding patients from
the nonresponding ones, to explain the causes of the
metabolic differences and to determine the influence of
sex on the therapy response.
Methods
Characteristics of patient groups
The study was approved by Ethical Committee of the
Maria Sklodowska-Curie National Research Institute of
Oncology, and written informed consent was obtained
from each patient. The retrospective study was con-
ducted on the HNSCC patients treated oncologically in
the 1st Radiation and Clinical Oncology Department of
Maria Sklodowska-Curie National Research Institute of
Oncology, Gliwice Branch. The study group consisted of
35 men and 18 women, all Caucasians, at the median
age of 57 (22–74) years. Induction chemotherapy is
mainly used in the advanced cancer stages (LA-HNSC
C), therefore the patients in the current study where
staged to TNM IV (81.1%) and III (18.9%). There were
no patients with metastases (M0 = 100%), all patients
were HPV negative.
The protocols (regimens) of iCHT were as follows:
a) 3 cycles of TPF administered every 21 days
(docetaxel 75 mg/m2, followed by cisplatin 100 mg/
m2 on day 1, and 5-fluorouracil 1000 mg/m2 per
day administered as a continuous 24-h infusion for
4 days) followed by chemoradiotherapy delivered as
a sequential therapy - 21 patients [4]
or
b) 4 cycles of TPF administered every 21 days
(docetaxel 75 mg/m2 of body-surface area, followed
by cisplatin 75 mg/m2 on day 1, 5-fluorouracil 750
mg/m2 per day administered as a continuous 24-h
infusion for 4 days) followed by radiotherapy as a
sequential therapy - 2 patients [5]
or
c) 3 cycles of PF administered every 21 days (cisplatin
100 mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 as
a continuous 24-h infusion for 4 days) followed by
chemoradiotherapy with cisplatin delivered as a se-
quential therapy – 28 patients [4, 23]
or
d) 3 cycles of paclitaxel and carboplatin (PC)
administered every 21 days (175 mg/m2) and
carboplatin at a dose calculated using the Calvert
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formula area under the curve of 5 followed by
chemoradiotherapy with carboplatin delivered as a
sequential therapy – 2 patients [24].
Induction chemotherapy was administered every 3
weeks (defined as one cycle) for up to four cycles, unless
progressive disease, unacceptable toxic effects, or with-
drawal from the study occurred earlier. The patients re-
ceived one (9 patients), two (6 patients), three (36
patients) or four iCHT cycles (2 patients). The patients
with an incomplete iCHT were treated with the TPF (7
patients) and PF (8 patients) regimens. The administra-
tion of the antiemetics, antibiotics, steroids, hydration,
diuretics was mandatory during each cycle.
In aim of quantifying the patients’ general well-being
and the activities of daily life their performance status was
measured to determine whether they can receive chemo-
therapy. All of them had 2 or less performance status by
WHO/ECOG/Zubrod scale, the adequate hematologic,
renal, and hepatic functions, without serious comorbidities
and was able to receive iCHT. During chemotherapy, the
patients were monitored clinically and with the laboratory
tests on day 1 of each cycle, before starting the treatment.
The iCHT timing depended on the treatment tolerance
measured by the Common Terminology Criteria for Ad-
verse Events (CTCAE) - the standardized classification of
adverse effects of cancer therapy [25]. CTCAE uses a
range of grades from 1 to 5 (1 – Mild, 2 – Moderate. 3 –
Severe, 4 - Life-threatening, 5 – Death). The most com-
mon causes of the delays in cycles’ administration were
neutropenia or/and leukopenia grade 3 and more.
Assessment of treatment response to induction
chemotherapy
The treatment response to induction chemotherapy was
evaluated by the clinical, fiberoptic and radiological ex-
aminations. The TNM Classification of Malignant Tu-
mors v. 7 was used before and after iCHT as a globally
recognized standard for classifying the extent of cancer
spread (T - tumor, N – regional involved lymph nodes,
M - distant metastasis). The prefix modifiers were used
as follows: “c” – a stage determined from the evidence
acquired before the treatment (including the clinical
examination, imaging, endoscopy, biopsy, surgical ex-
ploration), “y” – a stage assessed after iCHT in the same
way as “c”. In our study most of the patients were the
significant responders (yTNM lower than cTNM and an
explicit percentage volumetric radiological remission)
and iCHT was followed by radiotherapy or concurrent
chemoradiotherapy in compliance with a schedule.
The primary lesions were measured within the head
and neck in the images taken before (preCHT) and after
induction chemotherapy (postCHT) in the radiology de-
partment of the Maria Sklodowska-Curie National
Research Institute of Oncology. If an incomplete cycle of
induction chemotherapy and immediate subsequent rad-
ical radiochemotherapy was performed (7 patients), the
CT scan for the radiotherapy planning was used after in-
duction chemotherapy for a sake of comparison. All
types of imaging capable of obtaining a multiplanar re-
construction (MPR) were considered (CT, MR and PET-
CT scans).
All volumetric measurements were performed by a
qualified radiologist using the ‘MR Segmentation’ tool
which is available with Siemens Healthcare syngo.via
software, version VB20A. The following procedure was
applied for each lesion. After the image was viewed with
the ‘MR Basic’ system, the ‘MPR view’ was enabled.
Then the ‘MR Segmentation tool’ was selected from the
‘VOI selection’ list to evaluate an arbitrary VOI in a
semiautomatic way. The segmentation was performed
using the ‘brush based segmentation’ tool. The middle
part of the lesion was marked by tracing it with a green
line, its boundary was enclosed by tracing it with a red
line. The lesion area was defined in this way on every
third layer. The starting and ending layers of the volume
segmentation were marked with a solid red area only. Fi-
nally, the lesion volume was calculated, measured in
cubic centimeters, and limited by a green outline.
The percentage of tumor regression was calculated
using the following formula: 100-(postCHT tumor vol-
ume)*100/(preCHT tumor volume). The clinical re-
sponse to iCHT was expressed as a difference of cT-yT
and cN-yN.
Serum samples collection
The overnight fasting blood samples from the peripheral
vein were collected before (preCHT) the first cycle of
iCHT and within a week preceding the start of radiation
therapy (postCHT), at the median of 45 days after the
end of iCHT. The blood samples were incubated for 30
min at room temperature and then centrifuged (1000×g,
10 min) to remove a clot, and stored frozen at − 80 °C
until the NMR measurements are performed. The total
number of 130 samples were collected.
Sample preparation for NMR spectroscopy
The serum samples were thawed in two steps (at 4 °C
and at room temperature) and mixed with the phosphate
buffer (pH 7.4) containing D2O and TSP. The aliquots of
600 μl of the solution were transferred into 5 mm
Wilmad WG-1235-7 NMR tubes (Wilmad Labglass,
USA) and kept at 4 °C until the NMR analysis.
Measurement protocol
The same measurement protocol as in our previous
metabolomic studies [26, 27] was applied. The 1H NMR
spectra were acquired on a Bruker 400MHz Avance III
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spectrometer (Bruker Biospin, Rheinstetten, Germany)
equipped with a 5 mm PABBI probe. The quality control
tests were performed at every measurement day. The
NMR probe tuning and matching, shimming, determin-
ation of the transmitter offset value for the water pulse
presaturation and 90° pulse adjustments were always
made for each sample. The receiver gain was set to 90.5
and the temperature to 310 K for all experiments. Four
different 1H NMR spectra – NOESY (1D nuclear Over-
hauser enhancement spectroscopy), CPMG (Carr-Pur-
cell-Meiboom-Gill), diffusion edited (DIFF) and J-
resolved (JRES) – were acquired for each serum sample.
The characteristics of the acquired spectra as well as the
pulse sequence parameters are given in Supplementary
Material (Table S1).
Spectra post-processing
All 1D spectra were processed with a line broadening of
0.3 Hz and automatically phase corrected (in Topspin
software from Bruker Biospin), referenced to the methyl
doublet of alanine at 1.5 ppm and bucketed over the re-
gion 9.0–0.5 ppm with the bucket width set to 0.002
ppm using AMIX software (Bruker Biospin). The
spectrum region of water (5.15–4.38 ppm, d = 0.77 ppm)
was removed from the analysis in order to prevent vari-
ation in each sample. No normalization was applied.
This is the standard processing protocol used in our
metabolomic lab [26, 27].
Metabolites identification
The metabolites identification was done based on the
comparisons with the reference compounds library (in
Chenomx NMR Suite Professional (Chenomx Inc., Ed-
monton, Canada)), as well as on the multiplicity and sca-
lar couplings information extracted from the 2D JRES
spectra, and using the information from Human Metab-
olome Database (http://www.hmdb.ca/) and the available
literature.
Metabolite quantification
The low molecular weight metabolites were quantified
based on the 1D positive projections of the JRES spectra.
The diffusion edited spectra were used for quantification
of the lipid signals. The integrals were measured in the
spectral regions defined individually for each metabolite
using the “sum all points in region” method in AMIX
(Bruker Biospin) software.
Data analysis and validation of multivariate model
The data analysis was carried out using SIMCA-P+
(Umetrics, v. 14) software. The post-processed NMR
spectra were Pareto scaled and the distinction between
the preCHT and postCHT groups was done using the
orthogonal partial least squares discriminant analysis
(OPLS-DA). The OPLS-DA results are presented graph-
ically in two types of plots, which detailed description
and interpretation is available in [26]. The validation of
the OPLS-DA model was carried out using the internal
cross-validation.
The statistical significance of the estimated predictive
power of the OPLS-DA model was tested using permuta-
tion testing and ANOVA of the cross-validated residuals
(cv-ANOVA) as well as the external test set consisted of
24 serum samples acquired from 24 (LA-HNSCC) pa-
tients. The blood samples were collected after iCHT (23
patients) and in case of one patient only the pre-treatment
sample was included (the post-treatment one was ex-
cluded due to an insufficient blood sample volume). The
detailed description of the external test group is given in
Supplementary Material (Table S2).
The metabolites’ integrals were evaluated for their statis-
tical significance with the Wilcoxon signed-rank (WSR),
Mann-Whitney U (MWU), Kruskal-Wallis ANOVA
(KWA) and Spearman’s rank correlations (SRC) tests. The
significance threshold was set at 0.05. Statistica software
(Statsoft, v. 12) was applied for the univariate statistics.
Results
The detailed baseline characteristics of the patients
under the investigation is presented in Table 1.
The 400 MHZ 1H NMR CPMG median spectra from
the preCHT and postCHT groups are shown in Fig.S1.
Distinction between the preCHT and postCHT samples
using OPLS-DA
The results from the OPLS-DA analysis are presented in
Fig. 1. The OPLS-DA scores plot (Fig. 1a) shows a fair
separation between the pre- and postCHT classes, with a
small number of the mixing samples. The metabolites im-
portant for a class separation (lipids, alanine and glucose)
are identified based on the s-line plot (Fig. 1c). The sum-
mary of the OPLS-DA analysis is presented in Table 2.
The results of the validation procedure of the OPLS-DA
model are presented in Fig. 1b (the predicted (tPS) scores
plot for the external test set), Fig. S2 (the permutation
plot) and Table 2 (the misclassification table for the exter-
nal test set and cv-ANOVA).
Analysis of the mixing samples – investigation of
demographic and clinical factors
The OPLS-DA model is able to distinguish the preCHT
and postCHT samples, although the separation is not
very distinct due to the cloud of the mixing samples seen
in the OPLS-DA scores plot center (Fig. 1a). These mix-
ing samples are shown in Fig. 2, a modified version of
Fig. 1a, as two groups marked in red and green (if for a
particular patient a postCHT sample is identified as a
mixing one, the corresponding preCHT sample from
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this patient is also colored), whereas the non-mixing
ones are greyed out (the Grey group). We identified 10
postCHT cases shifted to the left side of the plot, to-
wards the negative values (the area occupied by the
preCHT samples), and 9 preCHT cases shifted to the
right side, towards the positive values (the area occupied
by the postCHT samples). The mixing postCHT samples
and their corresponding preCHT samples shifted to the
left side of the plot are colored in red (the Red group),
while the mixing preCHT samples and their correspond-
ing postCHT samples shifted to the right side of the plot
are colored in green (the Green group). Such
visualization is helpful to trace the trajectories of the
iCHT induced changes in the serum metabolic profiles.
As seen, for both Green and Red groups the weaker
metabolic response, measured as a distance between the
adequate preCHT-postCHT t [1] coordinates, is ob-
served than for the Grey, non-mixing group. This dis-
tance is the largest for the Grey group (KWA with the
p-values of 0.027 and 0.034 for the comparison with the
Red and Green ones) indicating the largest amplitude of
the metabolic alterations in the grey patients. Moreover,
except for one green patient (marked in Fig. 2 by the
arrow), the trajectories are correct, i.e. directed from left
(preCHT) to right (postCHT).
The box plot representation of the relative changes in
the metabolites identified by OPLS-DA and the WSR
test as important to differentiate the preCHT and
postCHT samples in the mixing and non-mixing pa-
tients is presented in Fig. 3. The lipid signals are signifi-
cantly increased after iCHT only in the non-mixing
patients (p < 0.000, the Grey group, WSR). The Green
patients start and end the treatment with the higher lipid
levels as compared to the values detected for the other
groups: the preCHT signal at 5.3 ppm is significantly
higher (p = 0.04, KWA) than for the grey, non-mixing
patients, whereas the postCHT lipid signals at 0.9 and
5.3 ppm are significantly higher than in the Red group
(p = 0.011 and 0.011 respectively, KWA), however the
treatment-related increase in this group is negligible.
Similarly, glucose is significantly decreased after iCHT
only in the non-mixing patients (p = 0.03, WSR). The de-
crease of alanine is significant in the Grey (p < 0.000,
WSR) and Red (p = 0.03, WSR) groups, while the NAG
is significantly decreased in the Grey (p = 0.005, WSR)
and Green (p = 0.04, WSR) ones.
The baseline demographic and clinical status of the
mixing patients was carefully investigated. The Green
patients had significantly lower initial nodal (cN) stage
when compared to the Red and the non-mixing (Grey)
ones (KWA with the p-values of 0.029 and 0.047, re-
spectively). There were no significant differences in the
cT and cTNM stages, tumor sites, sex, age. The treat-
ment related factors were also evaluated, showing no
significant differences in the number of the iCHT cycles,
overall treatment time (OTT) as well as utilization of the
particular iCHT scheme (TPF/PF) between the Grey,
Red and Green subgroups. Assessment of the iCHT in-
duced toxicity revealed mostly the grade 1 or 2 (low-
grade) toxicity according to the CTCAE. The most com-
mon low-grade hematological adverse events were:
anemia, leukopenia, thrombocytopenia and neutropenia
affecting 55, 34, 23 and 15% of the patients, respectively.
The high grade (grade 3 or 4) adverse events were
observed in 26% of the patients (neutropenia), 15% of
the patients (leukopenia) and 4% of the patients
(thrombocytopenia). The intensification of the side ef-
fects were at the same levels (KWA the p-values close to
1) within the subgroups.
Influence of baseline demographic and clinical factors on
the metabolic profile
The pretreatment lipids at 0.9, 1.3 and 5.3 ppm showed
a weak (SCR R = -0.39, − 0.35 and − 0.36, respectively)
inverse correlation with the initial TNM stage, while the
Table 1 Characteristics of the study group
Baseline patient characteristics of the main studied group
No. %
Age, years Median 57
Range 22–74
Sex Male 35 66
Female 18 34

















cTNM stage III 10 18.9
IVa 32 60.3
IVb 11 20.8
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Fig. 1 (See legend on next page.)
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pretreatment alanine correlated weakly with the initial
nodal stage (R = 0.37). Furthermore, the preCHT levels
of glucose and alanine were significantly (MWU p-values
of 0.009 and 0.001, respectively) higher in males (M)
compared to females (F), and thus in TPF compared to
PF due to the different M/F ratios in these groups (there
were fewer women treated with TPF than with PF, al-
though the difference was not statistically significant
(p = 0.15, MWU)).
The box plot representation of the relative changes in
the metabolites identified by OPLS-DA and the WSR
test as important to differentiate the preCHT and
postCHT samples in M and F is presented in Fig. 4. It is
clearly visible that only in M the levels of glucose and
alanine are lower after iCHT. There are no differences
in the glucose and alanine levels between M and F when
comparing the postCHT samples.
Correlation of the tumor regression after iCHT with the
metabolic profile
In our study, most of the patients (87%) were the signifi-
cant responders (as defined in Assessment of treatment
response to induction chemotherapy), however, the degree
of tumor shrinkage varied among the cases. The values of
the radiologically evaluated tumor volumes, the percent-
ages of the primary tumor regression and the initial and
post-treatment clinical staging are provided in Table S3.
Although the percentage of the tumor regression was
higher in the Grey group compared to Red and Green, the
difference was below the statistical significance. The per-
centage of the patients without the postCHT primary
tumor and the nodal downstaging were markedly higher
in Red (20%) and Green (22%) compared to Grey (8.8%),
however, due to the much larger size of the Grey group
than the Red and Green groups, this cannot be the basis
for a statistical inference.
In order to evaluate whether the magnitude of the
postCHT changes in the analyzed metabolites is corre-
lated with a clinically or radiologically measured re-
sponse to the treatment (as defined in Assessment of
treatment response to induction chemotherapy), the
SRC coefficients were calculated. The magnitude of the
metabolic alterations was expressed as the difference be-
tween the preCHT and postCHT levels of the metabo-
lites. The correlations were calculated for the whole
group as well as separately, for the subgroups stratified
according to the sex-related and metabolic responses
(See figure on previous page.)
Fig. 1 a The R2X scaled (the distances in the plot correspond to the explained variation) score plot obtained from the OPLS-DA analysis of the 1H CPMG NMR
spectra of the serum samples from the LA-HNSCC patients before (preCHT, ) and after (postCHT, ) induction chemotherapy. b The R2X scaled predicted
(tPS) score plot from the OPLS-DA analysis. The predicted samples from the external test set are correctly classified. c The OPLS-DA s-line plot indicating the
metabolites that differentiate the preCHT and postCHT groups. The correlation of the particular metabolites towards a segregation between the groups (p(corr))
is assessed according to the associated color bar
Table 2 The results from the OPLS-DA and statistical analyses
OPLS-DA model diagnostics










List of the important metabolites from the OPLS-DA model
Name ppm p(corr) p value Median ratio [%]
Metabolites increased after induction chemotherapy
1 Lipids 0.9 0.76 < 0.000 12.73
1.3 0.57 < 0.000 18.58
5.3 0.69 < 0.000 17.38
Metabolites decreased after induction chemotherapy
2 Alanine 1.48 0.33 0.0008 14.21
3 NAG 2.07 0.12 0.0002 9.03
4 Glucose 3.24 0.31 0.04 9.4
3.42 0.43 0.042 8.11
3.44 0.48 0.038 8.46
3.51 0.43 0.036 9.54
3.56 0.46 0.04 9.33
3.72 0.55 0.039 9.59
3.76 0.43 0.031 8.3
3.83 0.39 0.019 8.57
3.9 0.48 0.028 9.34
5.2 0.32 0.025 9.57
R2X — an amount of variation in the data that is correlated to class
separation; R2Y — a fraction of the class membership (Y) variation modeled
using the data matrix (X), this parameter tells how good is the separation
between two classes; R2X(o) — an amount of variation in the data that is
uncorrelated (orthogonal) to the class separation; Q2 — a predictive ability of
the OPLS-DA model; p(corr) — describes reliability of a variable, the closer to
one the better; p value – from the WSR test, Median ratio — shows the
between class differences in the peak integrals and is calculated as: 100 -
(lower median)/(higher median)*100. NAG — N-acetyl-glycoprotein.
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(Grey, Red, Green). The obtained results (only with a
statistical significance, i.e. with p < 0.05 and R > 3) are
listed in Table 3.
For the whole studied group, the clinically observed
regression of the primary tumor (cT-yT) is weakly corre-
lated with the postCHT increase of the lipid signals
(R = -0.31, SRC) and the decrease of NAG (R = 0.33,
SRC). In M this correlation is stronger (|R| ~ 0.4–0.57,
SRC), while in F it is absent. The increase in lipids is also
correlated with cT-yT in the Grey group (R = -0.38 and
− 0.46, SRC), while in the Green group, the cT-yT corre-
lates with the postCHT decrease of NAG (R = 0.73, SRC)
and alanine (R = 0.7, SRC) only. The percentage of the
primary tumor regression calculated based on the radio-
logical scans is worse explained by the metabolic profile
showing only the correlation with the postCHT increase
in lipids (M) (R = -0.45 and − 0.4, SRC) and the alanine
decrease (Green) (R = 0.77, SRC). The clinically observed
regression of the nodal stage, cN-yN, shows no correl-
ation with the important metabolites. Furthermore, no
metabolic correlations between the response to the
treatment in the Red group as well as in F is observed.
Discussion
In our previous works we identified the metabolic
changes in the blood serum related to the toxicity of
radio- and chemoradiotherapy in the HNSCC patients
[26, 27], however, the potential influence of induction
chemotherapy was not assessed. In the present work we
examine the serum metabolic profiles acquired before
the induction chemotherapy (preCHT) and within a
week before the start of a sequential radio- or chemora-
diotherapy (postCHT) and analyze the metabolic
changes in correlation with the conditions related to pa-
tient (age, sex), treatment (OTT, iCHT regimen, tox-
icity) and oncological disease (the TNM re-stage and
volumetric radiological remission after treatment).
The already gathered “omic” results suggest that to ex-
pand our understanding of the iCHT effects as well as of
the possible mechanisms of the toxicity induced by che-
moradiotherapy and of a subsequent radiation therapy
new studies should focus on the molecular mechanisms
and biochemical pathways [26–28]. As reveals from our
present study, the NMR-based metabolomics sheds
some light on the metabolic impact and efficacy of in-
duction chemotherapy. To the best of our knowledge,
this is the first NMR based metabolomics approach to
the identification of the biomarkers of induction chemo-
therapy in HNSCC.
OPLS-DA mixing serum samples – the measure of
response to iCHT
The OPLS-DA model with two orthogonal components
successfully separated the preCHT and postCHT serum
samples (Fig. 1a) as well as was able to predict the sam-
ple class from the external test group (Fig. 1b). However,
there were 19 identified mixing samples located in the
origin of the OPLS-DA scores plot (Fig. 1a). These
Fig. 2 The modified Fig. 1a with the colored mixing cases. The preCHT samples are denoted as the empty triangles: - the nonmixing patients, -
the mixing patients starting the treatment with a metabolic profile similar to that of the nonmixing group before the treatment and characterized by a
weaker metabolic response than the nonmixing ones, and - the patients starting the treatment with a metabolic profile similar to the Grey patients
after the treatment and characterized by a weaker metabolic response than the nonmixing ones. The corresponding postCHT samples are denoted as
the full color triangles: , , – the colors have the same meaning as for the preCHT samples. Within the mixing group, except for one patient
indicated by the green arrow directed from right to left, the trajectories of the metabolic changes are directed from left (preCHT) to right (postCHT),
as expected
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mixing – Red and Green samples (with the correspond-
ing pre/postCHT samples, 19 pairs) – were carefully
checked for any clinical, demographic or treatment re-
lated conditions that may affect their metabolic profiles.
The Green patients had significantly lower initial nodal
stage (cN), and presumably this is a reason of their spectra
to be shifted to the right in the OPLS-DA scores plot (the
postCHT direction). This statement can be supported by
the fact that in the study group the pretreatment lipids
are inversely correlated with the initial TNM stage, while
the pretreatment alanine correlates with the initial nodal
stage. The Green patients had the higher levels of the lipid
compounds as well as the lower level of alanine before the
treatment when compared to others (Fig. 3). The iCHT-
induced metabolic changes in the Green group show the
correct (except for one patient) trajectory, i.e. from left to
right (Fig. 2), however the response is significantly weaker
than in the Grey group. The median percentage of the
primary tumor regression is also lower in this group
(71.8%) compared to Grey (87%), although without a stat-
istical significance (Table S3).
In the Red subgroup, a weaker (compared to Grey)
metabolic response to iCHT was also observed with only a
significant decrease in the alanine postCHT level (Fig. 3)
and the median percentage of the primary tumor regres-
sion of 76.4% (Table S3). However, contrary to the Green
group, these patients do not differ significantly at baseline
(preCHT) from the Grey group. Their glucose, alanine,
NAG and lipids levels are similar to those for Grey and
they do not present any differences in sex, age and the ini-
tial tumor stage.
S-line plot – the metabolites important for discrimination
between the preCHT and postCHT classes
The metabolites important for discrimination between
the preCHT and postCHT classes were identified based
Fig. 3 The box plot representation of the relative changes in the metabolites identified by OPLS-DA as important to differentiate the preCHT and
postCHT samples. The results are presented separately for the mixing (Red, Green) and non-mixing (Grey) cases shown in Fig. 3
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Fig. 4 The box plot representation of the relative changes in the metabolites identified by OPLS-DA as important to differentiate the preCHT and
postCHT samples. The results are presented separately for males (M) and females (F). The decrease of glucose and alanine in M results from the
increased pre-treatment levels of these metabolites
Table 3 Results of the Spearman’s correlation between the clinically and radiologically measured response to the treatment and the
difference between the preCHT and postCHT metabolites
Response to the iCHT Correlation with the difference between the preCHT- postCHT metabolites
All patients Stratified according to metabolic response Sex stratified
Grey Red Green M F
cT-yT Lip 1.3 ppm (R = -0.31) ↑
NAG (R = 0.33) ↓
Lip 0.9 ppm (R = -0.38) ↑
Lip 1.3 ppm (R = -0.46) ↑
– Alanine (R = 0.7) ↓
NAG (R = 0.73) ↓
Lip 0.9 ppm (R = -0.55) ↑
Lip 1.3 ppm (R = -0.57) ↑
Lip 5.3 ppm (R = -0.47) ↑
NAG (R = 0.41) ↓
–
cN-yN – – – – – –
Primary tumor regression [%] – – – Alanine (R = 0.77) ↓ LIP 0.9 ppm (R = -0.45) ↑
Lip 1.3 ppm (R = -0.40) ↑
–
Legend: only statistically significant (p < 0.05, R > 0.3) values are presented. The arrows denote the increase/decrease of the particular metabolites, which is
correlated with the tumor downstaging/shrinkage.
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on the OPLS-DA s-line plot (Fig. 1c). The characteristic
metabolic changes for the postCHT samples are the in-
creased lipid signals with the simultaneous decreases in
alanine, glucose and NAG.
The effect of chemotherapy on the serum lipids has
been studied for at least three decades [20, 29–32],
mainly in breast cancer [33, 34]. To the best of our
knowledge no such studies has been conducted on
HNSCC patients, despite the fact that the lipid profile is
altered in this malignancy [35] as well as the main che-
motherapeutic agents for HNSCC (cisplatin, docetaxel
and 5-fluorouracil) are reported to induce dyslipidemia
[30, 32, 33]. There is no consensus in the literature
about the character of the chemotherapy-induced
changes in the lipid profile. However, an increase of
triglycerides (TG) and low-density lipoprotein (LDL)
cholesterol with a simultaneous reduction of high-
density lipoprotein (HDL) cholesterol is often reported
in breast cancer [29, 33, 34], wherein an increase in TG
could be a potential biomarker of effective chemother-
apy [29]. In colorectal cancer chemotherapy induces an
increase in total cholesterol, TG, HDL and lowers the
levels of LDL [31]. In the patients who favorably
responded to the treatment the increased levels of the
blood phospholipids were detected [20] and those with a
significant chemotherapy induced HDL elevation exhibit
a better 3-year disease free survival and 7-year overall
survival than those without [31]. In other types of can-
cers an increase of total cholesterol and LDL cholesterol
was also observed in the patients with a significant re-
sponse to the treatment [29].
The standard NMR acquisition protocol for the meas-
urement of the serum lipid signals (diffusion edited) and
the NOESY protocol provide information about the mo-
bile unsaturated lipids (the lipid signal at 5.3 ppm) as
well as the total cholesterol (the lipid signals at 0.9 and
1.3 ppm), however without an ability to identify the par-
ticular lipoprotein subclasses, i.e. VLDL (very low dens-
ity lipoprotein), LDL, HDL, etc. [36]. Nevertheless, these
NMR experiments are suitable to study a metabolic re-
sponse to iCHT.
Our results show a close relationship between the in-
crease of serum lipids and a favorable response to iCHT
– the postCHT increase in the lipid signals correlates
with the clinical stage reduction of the primary tumor
(Table 3). Such relation is not, however, observed in F as
well as in the patients with a weaker metabolic response
to iCHT (the Red and Green groups). In the Red group
with the lowest increase of lipids after iCHT one patient
discontinued chemotherapy due to myocardial infarc-
tion, one patient had a complete pathological response
and eight patients ended iCHT with a partial regression.
The median degree of the tumor regression in this group
was slightly lower as compared to the patients who had
significantly elevated lipids (Table S3). Also, in the
Green group the increase of the lipid signals was insig-
nificant, but the green patients showed the lowest me-
dian percentage of the primary tumor regression,
however, without a statistical significance. For the Grey
group the appropriate regression percentage was 87.01%.
In the whole study group 7 patients (6 women, 1 man)
showed no postCHT reduction of the clinical tumor and
nodal staging (cT = yT and cN = yN), in addition two of
them showed no radiological percentage of the tumor
regression after iCHT (Table S3). However, there was no
specific metabolic fingerprint differentiating them from
others (even when the non-responding female patients
where compared to those who favorably responded).
Another metabolic effect of induction chemotherapy is
lowering of the levels of glucose and alanine, two metab-
olites which blood levels are significantly positively cor-
related with each other [37]. However, their reduction
was observed only in the male patients and is due to the
increased pretreatment levels of these metabolites as
compared to the F group.
Possible explanation of the sex-related metabolic changes
in the post iCHT HNSCC patients
The detailed investigation of the available literature data
gives few possible explanations of these sex-related dif-
ferences: 1) Fasting blood glucose among males is found
to be higher than in females [38]; 2) Impaired fasting
glucose in pre-diabetes and diabetes is more prevalent in
men compared to women [39]; 3) Glucose metabolism
changes during the development and progression of oral
and tongue squamous cell carcinomas – the serum glu-
cose is elevated in oral cancer patients (compared to
controls) and is remarkably increased in patients with a
late stage disease than in those with an early stage [40].
In our study group, there were 3 confirmed diabetic pa-
tients (only the male ones, one with a type-1 diabetes;
no information about the pre-diabetic status in the
remaining patients), however their preCHT glucose and
alanine levels were not higher as compared to the
remaining male patients. In addition, after excluding the
diabetics, the difference in the preCHT glucose and
alanine levels between the M and F groups as well as the
postCHT drop of glucose and alanine in M were still
significant. Considering that men are more reluctant to
go to the doctor [41], thus their disease lasts longer (is
more advanced, i.e. more men with HNSCC present the
nodal stages 2 and 3 as well as the TNM stage IV than
women) [42], the metabolic alterations due to cancer
may be more pronounced. It seems to be reflected in the
structure of the study group where more men than
women presented higher cN stage (28.3% of the male
patients compared to 5.6% of the female patients pre-
sented cN3 stage and 14.3% of men compared to 33.4%
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of women presented cN stage of 0 or 1), with a differ-
ence close to a statistical significance (p = 0.061, MWU).
In consequence, although the influence of sex and dia-
betic status cannot be neglected, it seems likely that the
elevated preCHT glucose and alanine levels in M could
be due to the severity of the disease. On the other hand,
the decrease of glucose and alanine in the male patients
is not correlated with the clinical or radiological re-
sponse to the treatment (Table 3). However, such correl-
ation is observed in one of the subgroups with an
insignificant postCHT increase in lipids – in the Green
group the decrease in alanine is significantly correlated
with a favorable response to iCHT (Table 3). This is par-
ticularly surprising, because the green patients started
the treatment with the lowest level of alanine.
Furthermore, glucose and alanine are the biologically cor-
related metabolites, i.e. alanine is one of the major substrates
for gluconeogenesis during the increased demand for en-
ergy. Both these metabolites are strongly related to the pa-
tient’s nutritional status and their decreased levels in the
blood serum correlate with the weight loss during the anti-
cancer treatment [27]. In the study group, despite the higher
nodal stage, in M the levels of BMI and prealbumin are
higher than in F (p= 0.022 and 0.003 respectively, MWU).
However, contrary to the NMR detected metabolites, BMI,
prealbumin and albumin do not seem to be affected by
iCHT, showing no differences between the preCHT and
postCHT samples for both M and F (p≅ 0.5, WSR). Thus,
we can assume that the observed metabolic alterations are
probably not due to the differences in the nutritional status.
Inflammation marker vs. sex
NAG is an NMR marker of an inflammatory state [43] and
it correlates well with the level of C-reactive protein (a clin-
ical marker of inflammation) [26, 27], however in the study
group such correlation was observed only for M (p < 0.05,
R = 0.57 and 0.33 for preCHT and postCHT samples re-
spectively, SRC). Despite the more prevalent higher N stage
in the male patients, no differences were observed in the
preCHT NAG between the M and F groups. An inflamma-
tion reduction was observed in both sexes, however, such
effect was significant only in M (p = 0.001, WSR). Similarly
to glucose and alanine, it may, however, be related to the
initial tumor stage. Furthermore, the decrease of NAG after
iCHT correlates with a favorable response to the treatment,
although not in the F group (Table 3). We are not able to
find the explanation for the different response of the in-
flammatory marker between M and F.
Summary
NMR-based metabolomics can stratify the patients ac-
cording to their response to iCHT. Further studies on a
larger scale accounting for the sex and the clinical and
metabolic factors are warranted.
The study limitations
The findings of this study have to be seen in light of some
limitations already mentioned earlier. The main is the
small sizes of the studied groups. The importance of this
limitation is all the more important as the groups are het-
erogeneous in terms of sex, which turns out to influence
the observed effects. Moreover, the percentages of the pa-
tients in the Red, Green and Grey groups differ, which
makes the statistical inference difficult. The remedy is in-
creasing the groups – it will also significantly facilitate the
NMR detection of the metabolites of low intensity in the
serum NMR spectra, which in turn will help to determine
the metabolic paths responsible for the observed effects.
Undoubtedly, further studies should be performed on a
larger scale and accounting for sex and the clinical and
metabolic factors.
Conclusions
The NMR-based metabolomic study of the serum spectra
revealed that iCHT induces the marked changes in the
LA-HNSCC patients’ metabolic profiles. The molecular
response to iCHT involves an increase of the serum lipids
which is accompanied, however only in the males, by the
simultaneous decreases of alanine, glucose and N-acetyl-
glycoprotein (NAG). Furthermore, in M, the iCHT in-
duced changes in the lipid signals and NAG significantly
correlate with the primary tumor regression.
The metabolomic approach makes it also possible to strat-
ify the patients according to their response to iCHT. In the
weaker responding group two sub-groups were detected:
the first one with a significantly lower initial nodal stage and
the second one showing no differences in the initial clinical
and metabolic statuses. These effects are sex dependent.
Further studies on a larger scale accounting for the sex and
the clinical and metabolic factors are warranted.
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